ArticleHealth science reports2026
Global, Regional and National Burden of Hemolytic Disease and Other Neonatal Jaundice, 1980/90-2021, and Projections to 2050: A Global Burden of Disease Study 2021.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Hemolytic disease of the fetus and newborn and other forms of neonatal jaundice remain important causes of morbidity and mortality among children under five worldwide. Despite improvements in prevention and treatment such as Rh screening, phototherapy, and exchange transfusion, the burden remains uneven across regions. This study assessed global, regional, and national trends in incidence, prevalence, mortality, Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLLs), and Years Lived with Disability (YLDs) from 1980/1990 to 2021 using Global Burden of Disease (GBD) 2021 data. Methods: Data were obtained from the GBD 2021 study via the Global Health Data Exchange. Estimates of incidence, prevalence, deaths, DALYs, YLLs, and YLDs among children under five were analyzed globally and by region. For consistency with data availability, incidence, prevalence, mortality, DALYs, and YLDs were analyzed for the period 1990-2021, while YLLs were additionally assessed for the extended period 1980-2021. Joinpoint regression analysis was used to evaluate temporal trends and estimate the average annual percentage change (AAPC) with 95% confidence intervals. Results: Globally, the incidence of hemolytic disease and neonatal jaundice among children under five declined from 31,460.13 to 24,879.37 per 100,000 population between 1990 and 2021 (AAPC = -0.84%), while prevalence increased from 218,230.47 to 288,222.33 cases (AAPC = 0.90%). Mortality decreased from 16.59 to 5.11 per 100,000 (AAPC = -3.74%), and DALY rates declined from 1504.65 to 474.68 per 100,000 (AAPC = -3.67%). YLLs decreased from 2096.02 to 459.72 per 100,000 between 1980 and 2021 (AAPC = -3.64%), whereas YLDs increased slightly from 13.04 to 14.95 per 1000 (AAPC = 0.45%). Conclusion: Over the past four decades, mortality and overall disease burden have declined substantially, reflecting improvements in neonatal care. However, increasing prevalence and YLDs indicate a continuing burden of non-fatal complications. Marked regional disparities persist, particularly in Sub-Saharan Africa and South Asia, highlighting the need for strengthened and equitable neonatal health services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.